JPM24: ‘Diabesity’ duopoly between Novo, Lilly takes center stage

cafead

Administrator
Staff member
  • cafead   Jan 11, 2024 at 11:32: AM
via The CEOs of Eli Lilly and Novo Nordisk — rivals in the GLP-1 obesity market — addressed nagging questions at the 2024 J.P. Morgan Healthcare Conference.

article source